Accrufer® New Drug Submission accepted by Health Canada
Accrufer® New Drug Submission accepted by Health Canada
London, UK, June 24, 2021: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), confirms
Shield confirms it remains on track to launch Accrufer® in the US by end of June 2021